Risk of gradual change in eye colour, predominantly seen in patients w/ mixed coloured irides. Unilateral treatment can result in permanent heterochromia. Caution in chronic angle closure glaucoma, open angle glaucoma of pseudophakic patients & in pigmentary glaucoma; in inflammatory & neovascular glaucoma or inflammatory ocular conditions; in acute attacks of closed angle glaucoma; during peri-operative period of cataract surgery; patients w/ history of herpetic keratitis; w/ predisposing risk factors for iritis/uveitis; asthmatic patients; dry eye patients & patients w/ compromised cornea. Avoid in cases of active herpes simplex keratitis & in patients w/ history of recurrent herpetic keratitis specifically associated w/ prostaglandin analogues. Reports of macular oedema mainly in aphakic patients, in pseudophakic patients w/ torn posterior lens cap or anterior chamber lenses, or in patients w/ known risk factors for cystoid macular oedema. Reports of periorbital skin discolouration. May gradually change eyelashes & vellus hair in the treated eye & surrounding areas. Contains benzalkonium Cl. Remove contact lenses before instillation of the eye drops; reinsert after 15 min. If >1 topical ophth medicinal product is being used, administer at least 5 min apart. Minor influence on the ability to drive & use machines. Do not use during pregnancy. Do not use in breastfeeding women or breastfeeding should be stopped. No data available for preterm infants (<36 wk gestational age). Data in the age group <1 yr are limited.
Sign Out
